Pharma stocks suffered in October, particularly in North America. Across the globe, stock prices among the biggest pharmaceutical companies were down an average of 2% on the month, despite general market revivals in Asia. The generics sector was particularly badly hit but there were several major setbacks for branded pharma companies, too.
The 2% average stock decline among the Top 50 publicly traded drug companies represents a fall in market capitalization across...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.
The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.
Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.
